Oncology News | pharmaphorum

News

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Roche is on the brink of its first regulatory approval for what could be the first bispecific antibody targeting CD3 and CD20 – mosunetuzumab – after getting a positive opinion for the drug

News

Regeneron seeks CheckMate in immuno-oncology play

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in

News

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<

News

FDA starts speedy review of Enhertu in lung cancer

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

News

Patient backlog caused by COVID 'could take six years to cle...

The massive backlog in patient care across Europe resulting from the pandemic will take at least three years to clear and in some cases as long as six years, says a new study.

CHMP backs Roche's lymphoma bispecific mosunetuzumab

Regeneron seeks CheckMate in immuno-oncology play

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

FDA starts speedy review of Enhertu in lung cancer

Genmab and AbbVie prep filings for lymphoma bispecific

Patient backlog caused by COVID 'could take six years to cle...

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks